Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 4/20 | 0.53 |
| ▸ | KDR | P35968 | 6/20 | 0.47 |
| ▸ | AURKA | O14965 | 2/20 | 0.47 |
| ▸ | MET | P08581 | 2/20 | 0.47 |
| ▸ | TEK | Q02763 | 2/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.47 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.46 |
| ▸ | MERTK | Q12866 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | CSF1R | P07333 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | FLT4 | P35916 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30051321 | 0.91 | AXL (0.54) | AXLKDRAURKAMETTEK | |
| SCHEMBL29317904 | 0.91 | AXL (0.54) | AXLKDRAURKAMETTEK | |
| SCHEMBL30050356 | 0.90 | KDR (0.59) | AXLKDRAURKAMETTEK | |
| SCHEMBL29317871 | 0.90 | KDR (0.59) | AXLKDRAURKAMETTEK | |
| SCHEMBL30051021 | 0.87 | PDGFRA (0.56) | PDGFRAPDGFRBFGFR2 | |
| SCHEMBL29317863 | 0.87 | PDGFRA (0.56) | PDGFRAPDGFRBFGFR2 | |
| SCHEMBL29317818 | 0.86 | KDR (0.61) | AXLKDRAURKAMETTEK | |
| SCHEMBL30050696 | 0.86 | KDR (0.61) | AXLKDRAURKAMETTEK | |
| SCHEMBL29186571 | 0.85 | DDR2 (0.52) | AXLKDRMETPDGFRADDR2 | |
| SCHEMBL29186584 | 0.83 | EGFR (0.50) | PDGFRAPDGFRBFGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239806-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CHENGDU ANTICANCER BIOSCIENCE LTD (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240239806-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CHENGDU ANTICANCER BIOSCIENCE LTD (CN) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239806-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CYP27A1, CPT1A, OAT | AXL 4879/4885KDR 4885/4885AURKA 4724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.